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PCV14
ASPIRIN USE IS NOT ASSOCIATED WITH REDUCED MYOCARDIAL 
INFARCTION IN ELDERLY WITH TYPE 2 DIABETES WITH OR 
WITHOUT PRIOR HISTORY OF CARDIOVASCULAR DISEASE
Sirois C, Moisan J, Grégoire JP
Laval University, Québec, QC, Canada
OBJECTIVES: Aspirin is recommended for prevention of myocardial infarction (MI) 
in elderly with type 2 diabetes although the beneﬁ ts of aspirin therapy have not been 
well established in this population. We evaluated the association between aspirin use 
and myocardial infarction (MI) among elderly newly treated with oral antidiabetes 
drugs, according to whether or not they had prior history of cardiovascular disease. 
METHODS: Using Quebec administrative databases, we conducted two nested case-
control analyses within a population-based cohort of 39,680 individuals aged 66 
years, newly treated with an antidiabetes drug, who had not used aspirin, antiplatelet 
or anticoagulant drugs and had no MI in the year before cohort entry. In the ﬁ rst 
analysis, eligible individuals had no previous cardiovascular disease recorded in the 
database, whereas in the second analysis, eligible individuals had a known cardiovas-
cular disease. Cases were patients who had a MI. For each case, we selected ﬁ ve 
controls matched for age, year of cohort entry and sex using incidence density sam-
pling. Exposure to aspirin was deﬁ ned as current, past or none. Odds ratios (OR) of 
MI were calculated using paired multivariate conditional logistic regression. RESULTS: 
We identiﬁ ed 1101 cases of MI among the cardiovascular disease-free individuals. 
Neither current [OR = 1.03 (95% CI: 0.82–1.28)] nor past users [0.95 (0.74–1.24)] 
of aspirin had a signiﬁ cant different risk of MI than non users. There were 770 cases 
of MI among those individuals with a prior history of cardiovascular disease. Com-
pared with non users of aspirin, both past [1.72 (1.30–2.28)] and current users [1.33 
(1.03–1.71)] had a signiﬁ cant higher risk of MI. CONCLUSIONS: These results 
suggest that aspirin does not provide a cardiovascular protection to elderly individuals 
with type 2 diabetes.
PCV15
META-REGRESSION APPROACH TO IDENTIFY THE EQUIVALENCE 
DOSE RATIOS OF ROSUVASTATIN TO SIMVASTATIN AND 
ATORVASTATIN
Jakubczyk M1, Perkowski P2, Paweska J1, Macioch T1, Niewada M1, Rdzanek M2, Faluta T2
1HealthQuest sp z o.o., Warsaw, Poland; 2AstraZeneca Pharma Poland Sp. z o.o., Warsaw, 
Poland
OBJECTIVES: To identify the equivalent hypolipidemic doses of rosuvastatin com-
pared to atorvastatin and simvastatin. METHODS: A systematic review of clinical 
trials was conducted. The percentage reduction of baseline LDL cholesterol was used 
as a measure of clinical effectiveness. The weighted mean difference (WMD) of effec-
tiveness between comparators and rosuvastatin (separately) was calculated using the 
meta-regression approach, with logarithm of dosage ratio as an explanatory variable. 
Due to the heterogeneous baseline levels of cholesterol, the random effects model was 
used. As several observations came from single trials (various dosages of a given drug) 
a correlation of error terms may result. In a simpliﬁ ed, benchmark analysis no correla-
tions were assumed. In a full analysis it was assumed that: for two observations from 
a single trial regarding different patients the covariance equals the common variance 
of random-effects model; for two observations from a single trial with one group of 
patients in common the covariance is further increased by the variance of the effect 
for the shared group. Monte Carlo approach and Cholesky decomposition were used 
to calculate conﬁ dence intervals of equivalent dosage ratios taking into account the 
correlation of model estimates. RESULTS: In total 41 trials were found and used, 
allowing for 78 single comparisons of rosuvastatin with atorvastatin, and 25 with 
simvastatin. Dosage ratios of comparator to rosuvastatin used in the meta-regression 
amounted to 1:1, 2:1, 4:1, and 8:1. The full analysis yielded WMD = −8.64 + 
7.2*ln(dosage ratio) for atorvastatin and WMD = −15.94 + 7.55*ln(dosage ratio) for 
simvastatin. Benchmark analysis gave similar results. Resulting equivalence ratios 
amount to 3.32 for atorvastatin (95%CI: 2.93–3.79), and 8.26 (95%CI: 6.86–10.28) 
for simvastatin. CONCLUSIONS: Meta-regression approach allows for equivalence 
dosage analysis. Correlation issues need to be addressed for multiple treatment arms 
in a single study. Rosuvastatin yields equivalent hypolipemic effect for lower dosages 
than atorvastatin and simvastatin.
PCV16
THE EFFECT OF SITAXENTAN ON EXERCISE CAPACITY, 
HEMODYNAMIC FUNCTION, AND HEALTH-RELATED QUALITY OF LIFE 
IN ADULTS WITH PULMONARY ARTERIAL HYPERTENSION
Hwang LJ1, Liu X2, Teal SA3, Louie M1, Mychaskiw MA1
1Pﬁ zer Inc, New York, NY, USA; 2Aerotek, Houston, TX, USA; 3Pﬁ zer Ltd, Tadworth, 
Surrey, UK
OBJECTIVES: Pulmonary arterial hypertension (PAH) is progressive and fatal. Hemo-
dynamic parameters, physical functioning (PF), and health-related quality of life 
(HRQoL) worsen without treatment. The objective was to evaluate the distribution 
of changes in exercise capacity, hemodynamic parameters, and HRQoL in PAH 
patients treated with sitaxentan. Because cumulative distribution functions (CDFs) 
characterize treatment effects beyond conventional statistical signiﬁ cance (which is 
achievable in large studies with small changes that lack clinical meaning), this method 
was employed. METHODS: Adult PAH patients (n = 178) received 12 weeks of ran-
domized, double-blind treatment with placebo (n = 60) or sitaxentan 100 (n = 55) or 
300 (n = 63) mg once daily. The primary outcome measure was change in percent of 
predicted peak VO2 (PVO2); 6-minute walk distance (6MWD) measured exercise capac-
ity. Hemodynamic assessments included pulmonary and systemic vascular resistance 
(PVR and SVR, respectively), pulmonary capillary wedge pressure (PCWP), and cardiac 
index (CI). The Short Form-36 (SF-36) assessed HRQoL, including the PF domain. CDFs 
plotted the cumulative percentage of patients against percentage (and, separately, 
numeric) changes from baseline to week 12 in outcome measures. Kolmogorov-Smirnov 
tests assessed differences in separation between CDFs for sitaxentan and placebo. 
RESULTS: Signiﬁ cant differences between CDFs were observed for sitaxentan 300 mg 
(but not 100 mg) vs. placebo for both numeric and percentage change in percent of 
predicted PVO2 (P = 0.03). Signiﬁ cant differences occurred for sitaxsentan 100 and 
300 mg vs. placebo for 6MWD, PVR, SVR, and CI (P < 0.02 for each); the PCWP 
difference was signiﬁ cant only for percentage change at the 100-mg sitaxentan dose. 
No differences occurred for the SF-36 PF domain. CONCLUSIONS: Using CDF 
analysis incorporating the entire distribution of responses, sitaxentan signiﬁ cantly 
improved percent of predicted PVO2 (by numeric and percentage changes, 300-mg 
dose), 6MWD, PVR, SVR, CI, and PCWP (by percentage change, 100-mg dose), but 
not the SF-36 PF domain in PAH patients.
PCV17
RESPONSE PROFILES OF SILDENAFIL CITRATE ON EXERCISE 
CAPACITY, HEMODYNAMIC FUNCTION, AND HEALTH-RELATED 
QUALITY OF LIFE IN CHILDREN WITH PULMONARY ARTERIAL 
HYPERTENSION
Cappelleri JC1, Hwang LJ2, Mardekian J2, Mychaskiw MA2
1Pﬁ zer Inc, New London, CT, USA; 2Pﬁ zer Inc, New York, NY, USA
OBJECTIVES: Pulmonary arterial hypertension (PAH) is an ultimately fatal condition 
that may worsen hemodynamic parameters and contribute to diminished physical 
functioning and health-related quality of life (HRQoL). Although these relationships 
are well described in adults with PAH, they are not fully characterized in pediatric 
populations. METHODS: Children (aged 1–17 years) with PAH received 16 weeks 
of randomized, double-blind treatment with sildenaﬁ l citrate or placebo. The primary 
outcome measure, peak VO2 (PVO2), assessed cardiopulmonary exercise capacity in 
children developmentally capable of exercise. Secondary measures (for all patients) 
included mean pulmonary arterial pressure (mPAP), pulmonary vascular resistance 
index (PVRI), cardiac index (CI), and the Child Health Questionnaire-Parent Form 
(CHQ). Cumulative distribution functions (CDFs) plotted the cumulative percentage 
of patients against percentage changes (and also numeric changes) from baseline to 
week 16 in outcome measures. RESULTS: Of 234 randomized and treated children, 
106 were developmentally able to exercise; 148 to 221 provided non-exercise endpoint 
data. Descriptive separation between CDFs was evident for sildenaﬁ l versus placebo 
for percentage changes in PVO2, mPAP, PVRI, and CI. For example, 58 of 77 (75%) 
sildenaﬁ l-treated children had increases in the percentage change in PVO2 versus 13 
of 29 (45%) placebo-treated children. Descriptive separation between CDFs was not 
evident for CHQ domains of physical function, bodily pain, behavior, general health, 
and parental impact-time. Across all measures, an identical pattern of response proﬁ les 
was obtained when numeric (rather than percentage) changes were assessed. CON-
CLUSIONS: Cumulative distribution functions, which incorporate the entire distribu-
tion of responses, can enhance clinical interpretation of outcome measures. The 
distribution of responses on PVO2, mPAP, PVRI, and CI for sildenaﬁ l was descriptively 
more favorable compared with placebo, suggesting that sildenaﬁ l improves exercise 
capacity and hemodynamic function in children with PAH. Further research should 
elucidate the impact of disease and treatment on HRQoL in pediatric PAH.
PCV18
COMPARISON OF MIXED DYSLIPIDEMIAS AMONG HIGH 
CARDIOVASCULAR RISK PRIMARY CARE PATIENTS: RESULTS OF A 
POOLED ANALYSIS OF PRIMULA DATA FROM CANADA, SPAIN, 
SWEDEN, AND THE UNITED KINGDOM
Ambegaonkar BM1, Bash LD1, Jameson K2, Marentette M3, Nocea G4, Pettersson B5, 
Sazonov V1
1Merck & Co., Inc., Whitehouse Station, NJ, USA; 2MSD Ltd., Hoddesdon, UK; 3Merck Frost 
Canada Ltd, Kirkland, QC, Canada; 4Merck Sharpe & Dohme Ltd, Madrid, Spain; 5MSD, 
Sollentuna, Sweden
OBJECTIVES: Dyslipidemias involving elevated low-density lipoprotein cholesterol 
(LDL-C), low high-density lipoprotein cholesterol (HDL-C), and/or high triglycerides 
are correlates of cardiovascular disease (CVD). The degree to which risk persists after 
lipid modifying therapy (LMT), and varies between high risk populations, has not 
been well explored. We compare the prevalence of dyslipidemias§ before and after 
LMT among high CVD risk patients in clinical practice. METHODS: This is a pooled 
analysis of four observational, longitudinal, studies (PRIMULA) of primary care 
patients in Canada, Spain, Sweden, and the United Kingdom, ≥35 years old who initi-
ated LMT and continued therapy for >12 months. Data are reported for a total of 
12,768 high cardiovascular risk patients, more than half of whom had diabetes mel-
litus (DM), nearly a third with a history of CVD, and the remainder with a 10-year 
Framingham risk score (FRS) >20%. RESULTS: The majority (>95%) received statin 
monotherapy as their initial LMT. At baseline, those with a history of CVD had the 
lowest, and those with FRS > 20% the greatest prevalence of elevated LDL-C, elevated 
TG, low HDL-C and elevated LDL-C coupled with low HDL-C and/or elevated TG. 
After 12 months of follow-up, all high risk groups demonstrated improved lipid 
proﬁ les, though only among those with FRS > 20% did HDL-C improve. Persistent 
dyslipidemia was most rampant among those with a FRS > 20% and least among 
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those with a history of CVD. CONCLUSIONS: In each subgroup, there was a sub-
stantial improvement in LDL-C, while improvement of TG and HDL-C levels were 
moderate and negligible, respectively. Despite LMT, both single and mixed dyslipid-
emias were prevalent among high risk patients, particularly among those with DM 
and even more so among those with FRS > 20%. While the prevalence and persistence 
of dyslipidemia varied between groups, observations suggest that all may beneﬁ t from 
other types of LMT in addition to statins.
PCV19
EFFECTIVENESS OF ANTIHYPERTENSIVE AGENTS IN THE SECONDARY 
PREVENTION OF VASCULAR EVENTS AMONG PATIENTS WITH 
ISCHEMIC STROKE
Perreault S1, Cote R2, Dragomir A1
1Université de Montréal, Montréal, QC, Canada; 2McGill University, Montreal, QC, Canada
OBJECTIVES: Antihypertensive agents (AH) have been shown to reduce the risk of 
major cardiovascular (CVD) events. However, there is no large scale effectiveness 
studies which have assessed the relationship between adherence to AH medications 
and major CVD outcomes in high risk individuals that have suffered an ischemic 
stroke. The aim of the study was to evaluate the relationship between AH drug adher-
ence and vascular outcomes in a cohort of older patients hospitalized for an ischemic 
stroke and discharged in the community. METHODS: A cohort of 14,227 patients 
with ischemic stroke was reconstructed from RAMQ and Med-Echo databases. Eli-
gible subjects were 65 years and older and treated with AH agents between 1999 and 
2007. A nested case-control design was used to study major CVD outcomes. Every 
case was matched for age and duration of follow-up. The adherence to AH drugs was 
measured as the proportion of days’ supply of medication dispensed over a deﬁ ned 
period. Conditional logistic regression models were used to estimate the rate ratio of 
vascular events adjusting for covariables. RESULTS: Mean patient age was 75 years, 
54% were male, 23% had diabetes, and 47% had dyslipidemia, 38% had CAD, 6% 
MI and 14% had atrial ﬁ brillation. Adherence to AH agents ≥80% reduced the risk 
of vascular events (RR: 0.70; 0.64–0.77) compared to the one of <80%. Male gender, 
prior CVD, and non adherence to therapies for diabetes and dyslipidemia were risk 
factors. CONCLUSIONS: Higher adherence to AH therapy is linked with a risk 
reduction of vascular events among patients with ischemic stroke.
PCV20
COMPLIANCE WITH ANTIHYPERTENSIVE AGENTS AND THE ONSET 
OF END-STAGE RENAL DISEASE
Perreault S, Roy L, Lessard M, Dragomir A
Université de Montréal, Montréal, QC, Canada
OBJECTIVES: The correlation between severity of hypertension and risk of end-stage 
renal disease (ESRD) is well known. However, the impact of antihypertensive drug 
adherence on primary prevention of chronic kidney disease (CKD) has never been 
assessed. Our objective was to evaluate the impact of better adherence to antihyper-
tensive (AH) therapy on ESRD. METHODS: A cohort of 208,128 patients was 
reconstructed using RAMQ and MedEcho databases. Patients were eligible if they 
were between 45 to 85 years of age, had a new diagnosis of hypertension and were 
newly treated with AH drug between 1999 and 2007. a nested case-control design 
was used to study the occurrence of ESRD. Every case of ESRD was matched for age 
and duration of follow-up. Adherence level was assessed as a medication possession 
ratio. Conditional logistic regression models were used to estimate the rate ratio of 
ESRD adjusting for several covariables. RESULTS: Patients were at 65 years old and 
42% male. The mean high adherence level (80%) to AH therapy was 90%. We identi-
ﬁ ed 1026 cases with ESRD during follow-up. High adherence level (80%) to AH 
therapy compared to lower adherence level (<80%) was associated with a reduction 
of ESRD (RR: 0.81; 0.70–0.95). Risk factors for ESRD were CKD, gout, diabetes, 
coronary artery disease, chronic heart failure and peripheral vascular disease. CON-
CLUSIONS: The study suggests that better adherence to AH therapy is associated 
with risk reduction of new onset ESRD in hypertensive population.
PCV21
THE RELATIVE EFFECTIVENESS PROFILE OF DRONEDARONE USING 
THE NUMBER NEEDED TO TREAT (NNT) APPROACH
de Sauvebeuf C1, Chicoye A1, Hohnloser S2
1IMS Health, Puteaux, France; 2J.W. Goethe University Hospital, Frankfurt, Germany
Dronedarone is a new antiarrhythmic drug developed for the treatment of atrial ﬁ bril-
lation (AF). While numerous large cardiovascular (CV) clinical trials have assessed the 
efﬁ cacy of different compounds on morbidity and mortality endpoints, dronedarone 
is the ﬁ rst antiarrhythmic drug for AF for which a large randomized clinical trial 
(ATHENA) was designed to assess morbidity/mortality endpoints. OBJECTIVES: To 
perform an effectiveness analysis using the Number Needed to Treat (NNT) approach 
to compare dronedarone with other CV drugs in avoiding major CV events (CV death, 
CV hospitalization and stroke). METHODS: A literature search for 3 CV active 
medications (statins, angiotensin-converting enzyme inhibitors, angiotensin receptor 
blockers) was performed using PubMed from 1995 to present to identify clinical trials 
with endpoints comparable to those of ATHENA. NNTs were calculated using hazard 
ratios; different lengths of follow up were adjusted to one year, dividing each rate of 
events by the study duration. RESULTS: Twenty clinical trials were identiﬁ ed as 
having at least one endpoint comparable to ATHENA. Based on the ATHENA data, 
the NNT per year of treatment with dronedarone to avoid one “CV death”, one “CV 
hospitalization” and one stroke were 157, 11, and 172, respectively. Dronedarone 
was associated with a lower NNT to avoid a “CV death” compared to ramipril 
(HOPE, NNT = 239), pravastatin (LIPID, NNT = 255), and simvastatin (HPS, NNT 
= 325; 4S, NNT = 167), but a higher NNT vs. candesartan in selected chronic heart 
failure patients (CHARM, NNT = 123). NNTs for dronedarone to avoid one “CV 
hospitalization” and one stroke compared favorably to the other medications evalu-
ated. CONCLUSIONS: Pressure on health care budgets emphasizes the need to dem-
onstrate medical value, notably through NNTs which enable comparisons across 
interventions. Dronedarone has morbidity/mortality data (“CV death”, “CV hospital-
izations” and stroke) that compares favorably in terms of NNT to other CV therapies 
within their respective trial patient populations.
PCV22
THE INFLUENCE OF METEOROLOGICAL FACTORS ON CEREBRAL 
INFARCTION, INTRACEREBRAL HEMORRHAGE, SUBARACHNOID 
HEMORRHAGE AND TRANSIENT ISCHEMIC ATTACK
Kriszbacher I1, Csoboth I1, Fülöp A2, Boncz I1, Köhalmi A1, Müller Á1, Bódis J1
1University of Pécs, Pécs, Hungary; 2National Meteorological Service, Budapest, Hungary
OBJECTIVES: We have investigated, whether the time of onset of an acute cerebro-
vascular event demonstrates a seasonal variation, and whether it is inﬂ uenced by 
meteorological factors. METHODS: We examined patients admitted to Neurology 
Departments in Hungary between 2005 and 2007 with the diagnose of cerebral infarc-
tion, intracerebral hemorrhage, subarachnoid hemorrhage or transient ischemic attack 
(n = 178,092). Data was collected from the database of the Hungarian National Health 
Insurance Fund based on the International Classiﬁ cation of Diseases. Meteorological 
data was retrieved from the National Meteorology Service. RESULTS: Meteorological 
analysis showed, that an increase in average temperature on the previous day resulted 
in a signiﬁ cant drop of intracerebral hemorrhage incidence during Spring, Summer 
and Autumn (P < 0.01), while in case of cerebral infarction such decrease only 
occurred during Summer and Winter (P < 0.01), and for transient ischemic attack, 
only during Summer (P < 0.01).Examining atmospheric pressure, we found variations 
in case of cerebral infarction, intracerebral hemorrhage and transient ischemic attack. 
Morbidity rates of cerebral infarction increased during Summer, and decreased during 
Winter, whenever average atmospheric pressure values on the preceding day were 
higher (P < 0.01). Decrease in morbidity rates was observed for intracerebral hemor-
rhage and transient ischemic attack (P < 0.01). Considering relative humidity on the 
previous day, a marked variation showed for cerebral infarction during Spring (P < 
0.01), and for intracerebral hemorrhage during Summer (P < 0.01). No relationship 
was found with subarachnoid hemorrhage. CONCLUSIONS: Results reveal, that the 
occurrence cerebrovascular events shows typical variations depending on the season 
of the year, while certain meteorological factors inﬂ uence the development these also.
PCV23
DISCONTINUATION OF LOW-DOSE ACETYLSALICYLIC ACID 
TREATMENT FOR SECONDARY PREVENTION OF CARDIOVASCULAR 
OUTCOMES: INCIDENCE AND PREDICTORS
García Rodríguez LA1, Martín-Merino E1, Johansson S2
1Spanish Centre for Pharmacoepidemiological Research (CEIFE), Madrid, Spain; 2AstraZeneca 
R&D, Mölndal, Sweden
OBJECTIVES: To assess what proportion of patients treated with low-dose acetyl-
salicylic acid (ASA) for secondary prevention of cardiovascular events discontinue this 
treatment, and to identify risk factors for discontinuation. METHODS: The Health 
Improvement Network UK primary care database was used to identify individuals 
aged 50–84 years with ≥2 prescriptions of low-dose ASA (75–300 mg/day) in 2000–
2007 (n = 35,639). The study cohort was followed from the ﬁ rst day after the initial 
prescription until the earliest occurrence of one of the following: ASA discontinuation 
(a period of ≥90 days after the last prescription would have been used up [assuming 
full compliance], with no reﬁ ll of the prescription during this time); death; diagnosis 
of an alcohol-related condition or cancer; or the end of the study period. The mean 
follow-up time was 2.5 years. RESULTS: Almost one-third of patients discontinued 
low-dose ASA (n = 11,729; incidence: 13.1 per 100 person-years; 95% conﬁ dence 
interval [CI]: 12.9–13.4). The incidence of discontinuation was higher in the ﬁ rst year 
of follow-up (26.7 per 100 person-years; 95% CI: 26.1–27.3) than the rest of the 
study period (6.8 per 100 person-years; 95% CI: 6.6–7.0). The risk of discontinuation 
was 42–67% higher in patients with an initial indication of unstable angina, ischemic 
heart disease or cerebrovascular disease than those with an initial indication of myo-
cardial infarction. Current use of proton pump inhibitors (PPIs) was associated with 
a signiﬁ cant reduction in the risk of discontinuation (odds ratio [OR]: 0.92; 95% CI: 
0.87–0.98; compared with no PPI use). Individuals taking PPIs from the same time as 
their ASA treatment were at particularly low risk of ASA discontinuation (OR: 0.74; 
95% CI: 0.69–0.79). CONCLUSIONS: Discontinuation of low-dose ASA treatment 
is common, especially in the ﬁ rst year of treatment. Concomitant PPI use reduces the 
risk of ASA discontinuation.
PCV24
AN EPIDEMIOLOGICAL EVALUATION OF THE IMPACT OF 
PERCUTANEOUS CORONARY INTERVENTIONS ON THE LENGTH OF 
STAY AND MORTALITY OF PATIENTS HOSPITALIZED WITH ACUTE 
CORONARY SYNDROMES
Chevalier P, Lamotte M
IMS Health Consulting, Brussels, Belgium
OBJECTIVES: Randomized clinical trial comparing percutaneous coronary interven-
tions (PCI) and non-invasive treatment acute coronary syndromes mostly favour the 
